University of Tampere, Medical School, 33014 University of Tampere, Finland; Tampere Mental Health Centre, Hallituskatu 8 B, 33200 Tampere, Finland.
Neurosci Lett. 2011 Aug 21;501(1):20-4. doi: 10.1016/j.neulet.2011.06.031. Epub 2011 Jun 29.
The 5HT2A receptor gene (HTR2A) polymorphisms rs7997012 and rs6311 have in some earlier studies been associated with serotonin selective reuptake inhibitor (SSRI) treatment response in major depressive disorder (MDD), but the findings are inconsistent. The aim of the present study was to test for an association between two HTR2A polymorphisms (rs7997012 and rs6311), their interaction and the Montgomery and Åsberg Depression Rating Scale (MADRS) score change after ECT or SSRI treatment. The total number of patients was 218. All were treated in outpatient care. Of these, 119 subjects had treatment-resistant MDD and were treated with ECT and 99 were depressive patients treated with SSRI. Treatment response was assessed by MADRS. Patients scoring <8 on post-treatment MADRS were considered remitters. Neither rs7997012 nor rs6311 HTR2A polymorphism was significantly associated with MADRS score change alone, but the interaction between them and gender explained 14% of the variance in MADRS score change. The finding suggests an association between MADRS score change and interaction of HTR2A polymorphisms, rs7997012 and rs6311 and gender.
5HT2A 受体基因（HTR2A）多态性 rs7997012 和 rs6311 在一些早期研究中与选择性 5-羟色胺再摄取抑制剂（SSRI）治疗重度抑郁症（MDD）的反应有关，但研究结果不一致。本研究旨在检测两个 HTR2A 多态性（rs7997012 和 rs6311）、它们的相互作用以及蒙哥马利-Åsberg 抑郁评定量表（MADRS）评分在 ECT 或 SSRI 治疗后的变化之间的关联。总共有 218 名患者。所有患者均在门诊接受治疗。其中 119 名患者为治疗抵抗性 MDD，接受 ECT 治疗，99 名患者为接受 SSRI 治疗的抑郁患者。治疗反应通过 MADRS 评估。治疗后 MADRS 评分<8 的患者被认为是缓解者。单独的 HTR2A 多态性 rs7997012 或 rs6311 与 MADRS 评分变化均无显著相关性，但它们之间的相互作用与性别共同解释了 MADRS 评分变化的 14%。这一发现表明，MADRS 评分变化与 HTR2A 多态性 rs7997012 和 rs6311 及其与性别的相互作用之间存在关联。
